Ganaxolone

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 226 publications

Allosteric potentiation of GABAA receptor promotes survival and maturation of oligodendroglial cells in vitro via Ca2+/CaMK/AKT signaling pathway.

Allosteric potentiation of GABAA receptor promotes survival and maturation of oligodendroglial cells in vitro via Ca2+/CaMK/AKT signaling pathway.

Journal: American journal of physiology. Cell physiology

Published: May 29, 2026

Open-State Dynamics and Allosteric Modulation of the α1β3γ2 GABAA Receptor Stabilized by L9'T/S Substitutions.

Open-State Dynamics and Allosteric Modulation of the α1β3γ2 GABAA Receptor Stabilized by L9'T/S Substitutions.

Journal: Journal of chemical information and modeling

Published: May 25, 2026

Comprehensive evaluation of neurosteroid monotherapy and neurosteroid-midazolam combination therapy in mitigating the nerve agent soman-induced chronic neuropsychiatric dysfunction, epileptogenesis, neuroinflammation and neurodegeneration in pediatric models.

Comprehensive evaluation of neurosteroid monotherapy and neurosteroid-midazolam combination therapy in mitigating the nerve agent soman-induced chronic neuropsychiatric dysfunction, epileptogenesis, neuroinflammation and neurodegeneration in pediatric models.

Journal: Neuropharmacology

Published: April 11, 2026

Open-State Dynamics and Allosteric Modulation of the α1β3γ2 GABAA Receptor Stabilized by L9'T/S Substitutions.

Open-State Dynamics and Allosteric Modulation of the α1β3γ2 GABAA Receptor Stabilized by L9'T/S Substitutions.

Journal: bioRxiv : the preprint server for biology

Published: February 12, 2026

Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.

Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.

Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B.

Journal: The Journal of biological chemistry

Published: November 13, 2025

Ganaxolone as a promising therapeutic agent for Alzheimer's disease: signaling pathways and mechanistic insights-a narrative review.

Ganaxolone as a promising therapeutic agent for Alzheimer's disease: signaling pathways and mechanistic insights-a narrative review.

Journal: Inflammopharmacology

Published: October 01, 2025

Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives.

Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives.

Journal: Molecular biology reports

Published: August 26, 2025

Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review.

Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review.

Journal: Journal of clinical medicine

Published: July 31, 2025

Peripartum Depression Pharmacotherapies Targeting GABA-Glutamate Neurotransmission.

Peripartum Depression Pharmacotherapies Targeting GABA-Glutamate Neurotransmission.

Journal: Journal of clinical medicine

Published: July 31, 2025

Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy.

Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy.

Journal: Epilepsy research

Published: June 30, 2025

Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.

Tough to treat: What we know about managing PCDH19-related epilepsy - Systematic review.

Journal: Seizure

Published: June 30, 2025

Showing 1-12 of 226

Last Updated: 06/30/2026